The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Aslan (NASDAQ: ASLN) tumbled after its late-stage biliary tract cancer drug candidate flunked a pivotal study. Lipocine Inc's (NASDAQ: LPCN) investigational male sex hormone replacement therapy failed to win FDA nod, with the regulatory body shooting down the application for the third time.

Now, here are the key catalytic events for the unfolding week.